Targeted Therapy Triplet Shows Promise in R/R Richter’s Transformation and De Novo DLBCLApril 21st 2021
Anthony Mato, MD, MSCE, discusses the use of a triplet combination of the novel Bruton tyrosine kinase inhibitor DTRMWXHS-12, the mTOR inhibitor, everolimus, and the IMiD pomalidomide for the treatment of relapsed/refractory Richter’s transformation and de novo diffuse large B-cell lymphoma.
Phase 3 Study Supports Pembrolizumab in Treatment of Relapsed/Refractory Classical Hodgkin LymphomaApril 14th 2021
The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHLApril 12th 2021
Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHLApril 10th 2021
Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment LandscapeApril 8th 2021
While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.
Tuscano Reviews Treatment and Toxicity Management for a Patient With Classic Hodgkin LymphomaApril 5th 2021
Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.
Toxicities From Tafasitamab Monotherapy Are Less Severe After Discontinuing Lenalidomide in R/R DLBCLApril 4th 2021
The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.
Addition of Obinutuzumab and Venetoclax to Ibrutinib Overcomes Resistance in R/R MCL, Shows Activity in Newly Diagnosed MCLMarch 25th 2021
In relapsed and untreated patients with mantle cell lymphoma, the combination of obinutuzumab, ibrutinib, and venetoclax achieved molecular response rates and was found to be well tolerated, results from the phase 1/2 OAsIs trial demonstrate.
Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCLMarch 24th 2021
Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or BeyondMarch 6th 2021
The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin LymphomaMarch 5th 2021
Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell LymphomaFebruary 24th 2021
For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Axi-Cel Shows Activity in Relapsed/Refractory DLBCL Regardless of Chemo SensitivityFebruary 22nd 2021
Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.
Limited Following of Best Practices for CLL Observed in the Real-World SettingFebruary 20th 2021
Anthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic biomarker testing, treatment patterns and treatment dosing in a pool of 1461 patients with either chronic lymphocytic leukemia.
Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and TransplantFebruary 16th 2021
Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.
Axi-Cel Treatment Outcomes Correlate With Response to Prior Therapy in Refractory Large B-Cell LymphomaFebruary 9th 2021
Treatment with axicabtagene ciloleucel is less likely to induce responses in patients with refractory large B-cell lymphoma who have never achieved a complete response to any line of prior therapy, according to findings from a single-center retrospective analysis.
Responses to Liso-Cel Not Influenced by Prior Treatment With Anti-CD19 Agents in R/R Large B-Cell LymphomaFebruary 8th 2021
A post-hoc analysis of the practice-changing TRANSCEND NHL 001 trial revealed that exposure to anti-CD19 therapy in patients with relapsed/refractory large B-cell lymphoma, did not impact response to lisocabtagene maraleucel.
FDA Approves Liso-Cel CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaFebruary 5th 2021
The FDA has granted approval to lisocabtagene maraleucel a CD19-targeting chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received at least 2 prior lines of systemic therapy.
FDA Grants Accelerated Approval to Umbralisib in Relapsed/Refractory MZL and FLFebruary 5th 2021
The FDA has granted accelerated approval to umbralisib for the treatment of patients with relapsed or refractory marginal zone lymphoma who have received at least 1 prior regimen with anti-CD20 therapy, and for patients with follicular lymphoma who have received at least 2 prior systemic therapies.
Novel Prognostic and Stratification Index Determined Survival Outcomes for Burkitt LymphomaFebruary 5th 2021
A collaborative effort between Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has led to the discovery and validation of the novel Burkitt Lymphoma International Prognostic Index, a model for prognostication of patients with Burkitt lymphoma.